{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:18:58Z","timestamp":1775308738545,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.gene.2017.06.018","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T04:00:59Z","timestamp":1497412859000},"page":"202-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Impact of the BCR - ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"627","author":[{"given":"Golale","family":"Rostami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Jalaeikhoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2017.06.018_bb0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0010","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2017.06.018_bb0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0020","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.gene.2017.06.018_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.gene.2017.06.018_bb0030","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"De Lavallade","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2017.06.018_bb0035","first-page":"803","article-title":"Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia","volume":"4","author":"De Lemos","year":"2005","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.gene.2017.06.018_bb0040","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0045","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2013a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2017.06.018_bb0050","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.gene.2017.06.018_bb0055","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood.V78.12.3125.3125","article-title":"A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia","volume":"78","author":"Inokuchi","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0060","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0065","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL\u2013positive leukemias treated with imatinib in a single center","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.gene.2017.06.018_bb0070","first-page":"210","article-title":"Association of the responsiveness to interferon therapy with the bcr\/abl splicing pattern in Philadelphia chromosome positive chronic myelogenous leukemia","volume":"80","author":"Lee","year":"1992","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.gene.2017.06.018_bb0075","article-title":"b2a2 type bcr-abl transcript Chronic Myelogenous Leukemia (CML) patients in chronic Phase (CP) on Glivec achieve Complete Cytogenetic Remission (CCyR) earlier than those with b3a2","volume":"108","author":"Lomaia","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0080","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2017.06.018_bb0085","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to Imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.gene.2017.06.018_bb0090","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.V78.5.1155.1155","article-title":"Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature","volume":"78","author":"Mills","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0095","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood.V75.10.2035.2035","article-title":"Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase","volume":"75","author":"Morris","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0100","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2017.06.018_bb0105","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood.V80.7.1854.1854","article-title":"No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia [letter]","volume":"80","author":"Opalka","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0110","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0959-8049(00)00128-3","article-title":"The possible influences of B2A2 and B3A2 BCR\/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia","volume":"36","author":"Perego","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gene.2017.06.018_bb0115","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4238\/vol7-4gmr485","article-title":"Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr\/Abl fusion transcripts","volume":"7","author":"Polampalli","year":"2008","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.gene.2017.06.018_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2017.06.018_bb0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-009-0822-7","article-title":"Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts","volume":"89","author":"Sharma","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.gene.2017.06.018_bb0130","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2141.1995.tb08362.x","article-title":"Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival","volume":"89","author":"Shepherd","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.gene.2017.06.018_bb0135","first-page":"1648","article-title":"Chronic myeloid leukemia, BCR\/ABL transcript, response to alpha-interferon and survival","volume":"9","author":"The Italian Cooperative Study Group On Chronic Myeloid Leukemia","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2017.06.018_bb0140","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1939.1939","article-title":"Better molecular response to imatinib for patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) carrying the b3a2 transcript compared to b2a2","volume":"110","author":"Vega-Ruiz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.gene.2017.06.018_bb0145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/1097-0142(19950915)76:6<992::AID-CNCR2820760612>3.0.CO;2-L","article-title":"The breakpoint cluster region site in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations","volume":"76","author":"Verschraegen","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.gene.2017.06.018_bb0150","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2141.2002.03705.x","article-title":"Serial monitoring of BCR\u2013ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukemia","volume":"118","author":"Wang","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.gene.2017.06.018_bb0155","first-page":"247","article-title":"Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia","volume":"11","author":"Yaghmaie","year":"2008","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.gene.2017.06.018_bb0160","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.leukres.2014.07.003","article-title":"Outcome prediction by the transcript level of BCR-ABL at 3months in patients with chronic myeloid leukemia treated with imatinib-a single institution historical experience","volume":"38","author":"Yin","year":"2014","journal-title":"Leuk. Res."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111917304687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111917304687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T04:23:10Z","timestamp":1602303790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111917304687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":32,"alternative-id":["S0378111917304687"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2017.06.018","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2017.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}